Progression-free survival according to treatment arm. The probabilities of progression-free survival (95% CI) are shown below each time point. Tandem transplantation up front (arm A: —); single autologous followed by maintenance thalidomide and second autologous in case of relapse/progression (arm B: ). The probability of progression-free survival (95% CI) after randomization at 3 years in arm A is 57% (37–76) and in arm B is 85% (77–94).